Another cohort study reported that 63% of NSCLC patients showed onset of EGFR mutations and proliferation of cancer after treatment with EGFR-TKIs during re-biopsy, while a 33% frequency of T790M mutation was found [108]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.